SEC Form 4 · accession 0001140361-17-032394
NEVRO CORP · NVRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew H Galligan
Officer — Chief Financial Officer
Period of report
Aug 14, 2017
Accepted (ET)
Aug 16, 2017 · 11:49 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001444380
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 14, 2017 | M | 652 | $3.60 | A | 12,485 | D | |
| Common StockF1 | Aug 14, 2017 | M | 6,144 | $3.60 | A | 18,629 | D | |
| Common StockF1 | Aug 14, 2017 | M | 204 | $18.00 | A | 18,833 | D | |
| Common StockF3,F1 | Aug 14, 2017 | S | 7,000 | $82.3132 | D | 11,833 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $3.60 | Aug 14, 2017 | M | 652 | D | — | Sep 28, 2021 | Common Stock | 652 | 43,894 | D |
| Stock Option (Right to Buy)F4 | $3.60 | Aug 14, 2017 | M | 6,144 | D | — | May 14, 2023 | Common Stock | 6,144 | 36,286 | D |
| Stock Option (Right to Buy)F5 | $18.00 | Aug 14, 2017 | M | 204 | D | — | Nov 4, 2024 | Common Stock | 204 | 42,463 | D |
Explanation of responses
- F1Includes 6,833 restricted stock units.
- F2The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- F3The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $81.94 to $82.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4100% of the shares subject to the option are fully vested and exercisable.
- F51/48th of the shares subject to the option vest on each monthly anniversary measured from November 5, 2014 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.